Daypro and Jejunal haemorrhage - a phase IV clinical study of FDA data

Summary:

We study 2,849 people who take Daypro or have Jejunal haemorrhage. No report of Jejunal haemorrhage is found in people who take Daypro.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Dec, 08, 2022

No report is found.


What is Daypro?

Daypro has active ingredients of oxaprozin. It is often used in osteoarthritis. eHealthMe is studying from 2,834 Daypro users for its effectiveness, alternative drugs and more.

What is Jejunal Haemorrhage?

Jejunal haemorrhage (bleeding jejunal due to infection of bowel or intestine) is found to be associated with 19 drugs by eHealthMe.

Do you take Daypro and have Jejunal haemorrhage?

Check whether Jejunal haemorrhage is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Jejunal haemorrhage and when was it recovered:

Expand to all the drugs that have ingredients of oxaprozin:

Alternative drugs to, pros and cons of Daypro:

Jejunal haemorrhage treatments and more:

COVID vaccines that are related to Jejunal haemorrhage:

All the drugs that are associated with Jejunal haemorrhage:

All the conditions that are associated with Jejunal haemorrhage:

How the study uses the data?

The study uses data from the FDA. It is based on oxaprozin (the active ingredients of Daypro) and Daypro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: